<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="hwp">eLife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">04525</article-id><article-id pub-id-type="doi">10.7554/eLife.04525</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Medicine</subject></subj-group><subj-group subj-group-type="heading"><subject>Microbiology and Infectious Disease</subject></subj-group></article-categories><title-group><article-title>Mucosal effects of tenofovir 1% gel</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="author-18023"><name><surname>Hladik</surname><given-names>Florian</given-names></name><aff><institution content-type="dept">Department of Obstetrics and Gynecology</institution>, <institution>University of Washington</institution>, <addr-line><named-content content-type="city">Seattle</named-content></addr-line>, <country>United States</country><email>fhladik@fhcrc.org</email></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-20161"><name><surname>Burgener</surname><given-names>Adam</given-names></name><aff><institution content-type="dept">Department of Medical Microbiology</institution>, <institution>University of Manitoba</institution>, <addr-line><named-content content-type="city">Winnipeg</named-content></addr-line>, <country>Canada</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-20162"><name><surname>Ballweber</surname><given-names>Lamar</given-names></name><aff><institution content-type="dept">Vaccine and Infectious Diseases Division</institution>, <institution>Fred Hutchinson Cancer Research Center</institution>, <addr-line><named-content content-type="city">Seattle</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-20163"><name><surname>Gottardo</surname><given-names>Raphael</given-names></name><aff><institution content-type="dept">Department of Biostatistics</institution>, <institution>University of Washington</institution>, <addr-line><named-content content-type="city">Seattle</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-20167"><name><surname>Vojtech</surname><given-names>Lucia</given-names></name><aff><institution content-type="dept">Department of Obstetrics and Gynecology</institution>, <institution>University of Washington</institution>, <addr-line><named-content content-type="city">Seattle</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-20164"><name><surname>Fourati</surname><given-names>Slim</given-names></name><aff><institution>Vaccine and Gene Therapy Institute of Florida</institution>, <addr-line><named-content content-type="city">Port Saint Lucie</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-20165"><name><surname>Dai</surname><given-names>James Y</given-names></name><aff><institution content-type="dept">Department of Biostatistics</institution>, <institution>Univeristy of Washington</institution>, <addr-line><named-content content-type="city">Seattle</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-20166"><name><surname>Cameron</surname><given-names>Mark J</given-names></name><aff><institution>Vaccine and Gene Therapy Institute of Florida</institution>, <addr-line><named-content content-type="city">Port Saint Lucie</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-20168"><name><surname>Strobl</surname><given-names>Johanna</given-names></name><aff><institution content-type="dept">Vaccine and Infectious Diseases Division</institution>, <institution>Fred Hutchinson Cancer Research Center</institution>, <addr-line><named-content content-type="city">Seattle</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-20169"><name><surname>Hughes</surname><given-names>Sean M</given-names></name><aff><institution content-type="dept">Department of Obstetrics and Gynecology</institution>, <institution>University of Washington</institution>, <addr-line><named-content content-type="city">Seattle</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-20170"><name><surname>Hoesley</surname><given-names>Craig</given-names></name><aff><institution content-type="dept">Department of Medicine</institution>, <institution>University of Alabama</institution>, <addr-line><named-content content-type="city">Birmingham</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-20171"><name><surname>Andrew</surname><given-names>Philip</given-names></name><aff><institution>FHI 360</institution>, <addr-line><named-content content-type="city">Durham</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-20172"><name><surname>Johnson</surname><given-names>Sherri</given-names></name><aff><institution>FHI 360</institution>, <addr-line><named-content content-type="city">Durham</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-20173"><name><surname>Piper</surname><given-names>Jeanna</given-names></name><aff><institution content-type="dept">Division of AIDS, National Institute of Allergy and Infectious Diseases</institution>, <institution>National Institutes of Health</institution>, <addr-line><named-content content-type="city">Bethesda</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-20174"><name><surname>Friend</surname><given-names>David R</given-names></name><aff><institution content-type="dept">CONRAD</institution>, <institution>Eastern Virginia Medical School</institution>, <addr-line><named-content content-type="city">Arlington</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-20175"><name><surname>Ball</surname><given-names>T Blake</given-names></name><aff><institution content-type="dept">Department of Medical Microbiology</institution>, <institution>University of Manitoba</institution>, <addr-line><named-content content-type="city">Winnipeg</named-content></addr-line>, <country>Canada</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-20176"><name><surname>Cranston</surname><given-names>Ross D</given-names></name><aff><institution>University of Pittsburgh School of Medicine</institution>, <addr-line><named-content content-type="city">Pittsburgh</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-20177"><name><surname>Mayer</surname><given-names>Kenneth H</given-names></name><aff><institution content-type="dept">Fenway Health</institution>, <institution>Beth Israel Deaconess Hospital, Harvard Medical School</institution>, <addr-line><named-content content-type="city">Boston</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-20178"><name><surname>McElrath</surname><given-names>M Juliana</given-names></name><aff><institution content-type="dept">Department of Medicine</institution>, <institution>University of Washington</institution>, <addr-line><named-content content-type="city">Seattle</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-20179"><name><surname>McGowan</surname><given-names>Ian</given-names></name><aff><institution>Univeristy of Pittsburgh School of Medicine</institution>, <addr-line><named-content content-type="city">Pittsburgh</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-1180"><name><surname>Sgaier</surname><given-names>Sema</given-names></name><role>Reviewing editor</role><aff><institution>Bill &amp; Melinda Gates Foundation</institution>, <country>India</country></aff></contrib></contrib-group><pub-date date-type="pub" publication-format="electronic"><day>03</day><month>02</month><year>2015</year></pub-date><volume>4</volume><elocation-id>e04525</elocation-id><supplementary-material><ext-link xlink:href="elife-04525-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material><history><date date-type="received"><day>27</day><month>08</month><year>2014</year></date><date date-type="accepted"><day>02</day><month>02</month><year>2015</year></date></history><permissions><license xlink:href="http://creativecommons.org/publicdomain/zero/1.0/"><license-p>This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">Creative Commons CC0</ext-link> public domain dedication.</license-p></license></permissions><abstract><p>Tenofovir gel is being evaluated for vaginal and rectal pre-exposure prophylaxis against HIV transmission.  Because this is a new prevention strategy, we broadly assessed its effects on the mucosa.  In MTN-007, a phase-1, randomized, double-blinded rectal microbicide trial, we used systems genomics/proteomics to determine the effect of tenofovir 1% gel, nonoxynol-9 2% gel, placebo gel or no treatment on rectal biopsies (15 subjects/arm).  We also treated primary vaginal epithelial cells from four healthy women with tenofovir in vitro.  After seven days of administration, tenofovir 1% gel had broad-ranging effects on the rectal mucosa, which were more pronounced than, but different from, those of the detergent nonoxynol-9.  Tenofovir suppressed anti-inflammatory mediators, increased T cell densities, caused mitochondrial dysfunction, altered regulatory pathways of cell differentiation and survival, and stimulated epithelial cell proliferation.  The breadth of mucosal changes induced by tenofovir indicates that its safety over longer-term topical use should be carefully monitored.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group></article-meta></front><back><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Human subjects: MTN-007 (ClinicalTrials.gov registration NCT01232803) was a phase 1, double blind, placebo-controlled trial in which participants were randomized to receive rectal reduced glycerin tenofovir 1%, nonoxynol-9 (N-9) 2% or hydroxyethylcellulose (HEC) gels, or no-treatment (1:1:1:1), at three clinical research sites (Pittsburgh, PA; Birmingham, AL; and Boston, MA). The study protocol was approved by IRBs at all three sites. All participants gave written informed consent. The study details, and general safety and acceptability data, have been published elsewhere (McGowan I et al. [2013] A phase 1 randomized, double blind, placebo controlled rectal safety and acceptability study of tenofovir 1% gel [MTN-007]. PLoS ONE 8: e60147). CONSORT checklist, CONSORT flow chart and MTN-007 IRB approval were submitted with the prior paper, and are attached again here.</p></fn></fn-group></back></article>